Does Sanofi's $50 Million Milestone Payment to MannKind Corp. Matter?
Sanofi has made a $50 million milestone payment to MannKind, but Afrezza's success or failure is far more important to MannKind this year.
Great News! An Exciting New Drug for Depression May Be on the Way
In phase 3 trials, Alkermes' ALKS-5461 shows promise for the treatment of depression.